Published in Autoimmune Dis on September 09, 2015
Vitiligo blood transcriptomics provides new insights into disease mechanisms and identifies potential novel therapeutic targets. BMC Genomics (2017) 0.75
Agrobacterium sp.-derived β-1,3-glucan enhances natural killer cell activity in healthy adults: a randomized, double-blind, placebo-controlled, parallel-group study. Nutr Res Pract (2017) 0.75
Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 25.63
IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol (1991) 11.04
Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res (2003) 3.07
A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin. J Invest Dermatol (2012) 2.05
Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56
CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med (2014) 1.50
New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res (2002) 1.42
Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest (2003) 1.41
Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. J Immunol (2010) 1.24
Vitiligo: pathomechanisms and genetic polymorphism of susceptible genes. Indian J Exp Biol (2006) 1.09
Cytokines in autoimmune disorders. Int Rev Immunol (1998) 1.08
Vitiligo: a manifestation of apoptosis? Am J Clin Dermatol (2002) 1.07
Oxidative stress in smokers and non-smokers. Inhal Toxicol (2007) 1.03
Modulation of melanocyte intercellular adhesion molecule-1 by immune cytokines. J Invest Dermatol (1990) 1.03
Immunological pathomechanisms in vitiligo. Expert Rev Mol Med (2001) 1.01
Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol (2004) 0.97
Decreased regulatory T-cells and CD4(+) /CD8(+) ratio correlate with disease onset and progression in patients with generalized vitiligo. Pigment Cell Melanoma Res (2013) 0.95
A study of blood CD3+, CD4+, and CD8+ T cell levels and CD4+:CD8+ ratio in vitiligo patients. Indian J Dermatol Venereol Leprol (2011) 0.89
IFN-γ, IL-21, and IL-10 co-expression in evolving autoimmune vitiligo lesions of Smyth line chickens. J Invest Dermatol (2011) 0.89
Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in Vitiligo patients. Indian J Dermatol (2012) 0.88
Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus. Br J Dermatol (2009) 0.87
T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo. Clin Chim Acta (2013) 0.86
Possible pathogenetic relevance of interleukin-1 beta in "destructive" organ-specific autoimmune disease (Hashimoto's thyroiditis). Ann N Y Acad Sci (1999) 0.84
Evaluation of the effect of disease duration in generalized vitiligo on its clinical response to narrowband ultraviolet B phototherapy. Photodermatol Photoimmunol Photomed (2012) 0.83
Vitiligo. Int J Dermatol (1988) 0.83
Expression of IL-17 and COX2 gene in peripheral blood leukocytes of vitiligo patients. Iran J Allergy Asthma Immunol (2011) 0.83
Association of FOXP3 (rs3761548) promoter polymorphism with nondermatomal vitiligo: A study from India. J Am Acad Dermatol (2013) 0.81
Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in onset and progression of generalized vitiligo. J Interferon Cytokine Res (2013) 0.81
Erythrocyte malondialdehyde and glutathione levels in vitiligo patients. Ann Dermatol (2010) 0.81
Oxidative stress and immune system in vitiligo and thyroid diseases. Oxid Med Cell Longev (2015) 0.79